Navigation Links
Simeprevir Administered Once Daily as Part of Combination Therapy Demonstrates Sustained Virologic Response in Treatment-Naive and Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
Date:11/2/2013

ated with simeprevir in clinical trials.

In October, Janssen Pharmaceuticals, Inc. acquired the investigational compound GSK2336805, an NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic HCV, from an affiliate of GlaxoSmithKline plc. Since being acquired, the compound has been renamed JNJ-56914845. Janssen Pharmaceuticals plans to initiate Phase 2 studies to evaluate the use of JNJ-56914845 in interferon-free combinations with simeprevir and TMC647055, the company's non-nucleoside polymerase inhibitor, for the treatment of chronic HCV in adult patients with compensated liver disease.

For additional information about simeprevir clinical trials, please visit www.clinicaltrials.gov.

About Janssen R&D Ireland                  
At Janssen, we are dedicated to addressing and solving some of the most important unmet medical needs of our time in oncology, immunology, neuroscience, infectious diseases and vaccines, and cardiovascular and metabolic diseases. Driven by our commitment to patients, we develop innovative products, services and healthcare solutions to help people throughout the world. Janssen R&D Ireland is part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Please visit http://www.janssenrnd.com for more information.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen R&D Ireland, any o
'/>"/>

SOURCE Janssen R&D Ireland
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Simeprevir Data in Hepatitis C Patients to be Presented at the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
2. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
3. U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
4. Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
5. Findings from Two Phase 3 Studies of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
6. Janssen Submits New Drug Application to U.S. FDA for Simeprevir (TMC435) for Combination Treatment of Adult Patients with Genotype 1 Chronic Hepatitis C
7. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
8. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
9. MCOs Shifting Control Over Office-Administered Products from Medical to Pharmacy Benefit, Particularly Affecting Rheumatoid Arthritis Therapies
10. American Journal of Medicine Publishes Hypertension Study Comparing the Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone versus Azilsartan Medoxomil Co-administered with Hydrochlorothiazide
11. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... DUBLIN , October 24, 2014 ... has announced the addition of the "Global ... report to their offering.      (Logo: ... Concentrates Industry Report 2014 is a professional and ... hemodialysis concentrates industry with a focus on the ...
(Date:10/25/2014)... HOUSTON , Oct. 24, 2014   Metanome, ... of comprehensive metagenomic services and data analysis, was the ... Mass ) Phase I/II clinical trial of SER ... with recurrent Clostridium difficile infections (CDI). ... of Seres Health,s R&D and clinical programs. Such genomic ...
(Date:10/25/2014)... 2014 Burzynski Research Institute, Inc. (BRI) announced ... has given the company permission to conduct an open-label ... 3 months of age with a diffuse intrinsic brainstem ... of five treatment groups based on their age and ... DIPG. The primary study endpoint is a decrease in ...
Breaking Medicine Technology:Global and Chinese Hemodialysis Concentrates Industry Report 2014 2Global and Chinese Hemodialysis Concentrates Industry Report 2014 3Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2
... , MORRISTOWN, N.J. , May 7 Watson Pharmaceuticals, ... Laboratories, Inc. has reached a settlement with Teva Women ,s Health, ... estradiol tablets USP, 0.15 mg/0.03 mg) product. , ... On December 13, 2007 , Teva filed a ...
... , May 7 Patients treated ... clinical improvement at two years, according to interim ... today as a late-breaking clinical trial at the ... Annual Scientific Sessions. The prospective, single-arm study is ...
Cached Medicine Technology:Watson Reaches Settlement with Teva Over Seasonale(R) 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 2Drug-Eluting Peripheral Stent Continues to Show Positive Data at Two Years 3
(Date:10/25/2014)... The global HCIT outsourcing market is forecast ... $50.4 billion by 2018 from $35 billion in 2013. ... industry are driving the HCIT outsourcing market. These industries ... on core business, reduce operational and maintenance costs, increase ... hiring and training costs), share risk, and quickly implement ...
(Date:10/25/2014)... October 25, 2014 The ... which verifies IT-accessibility for disabled users by disabled ... logo to Mackin Educational Resources of Burnsville, ... management system and to the Minnesota Alliance for ... "Own Best Medicine" website. Both organizations ...
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... Oct. 24, 2014 (HealthDay News) -- Researchers who ... their findings are cause for concern. The ... are raised for human consumption contribute to the ... according to background information from the study. ... sicken about 2 million people and kill about ...
(Date:10/22/2014)... At a time when the national concussion ... at all levels, the UPMC Sports Medicine Concussion ... where two powerful messages are lost: Concussions can be ... full recoveries every day. , In striving to shift ... research, UPMC and the Concussion Program are unveiling the ...
Breaking Medicine News(10 mins):Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 2Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 3Health News:Global HCIT Outsourcing Market to Grow at 7.6% CAGR to 2018 Says a Premium Research Report Available at ReportsnReports.com 4Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 2Health News:IT-Accessibility Award Granted to Education and Health Care for Section 508/WCAG 3Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 2Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 3Health News:University of Pittsburgh Medical Center Launches Initiative to Emphasize Concussions Are Treatable 4
... ... The VitaLogikTM 6000 is a pre-configured multi-parameter Patient Monitor with ... uninterrupted vital signs, monitoring. An integrated wireless local area network solution ... new propriety internal wireless card and based on the IEEE Compliance ...
... ... the launch of the EliteCustom® Vacuum Therapy System as a conservative treatment option ... ... announces a new Vacuum Therapy Supply Program with the launch of the EliteCustom® ...
... ... ... 22, 2010 -- Aprima Medical Software , a leading developer of electronic health ... reseller agreement with Pacific Medical IT Inc., a California-based leader in providing local medical ...
... ... has designated Houston Northwest Medical Center as a Blue Distinction Center for Spine Surgery. ... Houston, TX (Vocus) February 22, ... as a Blue Distinction Center for Spine Surgery. Blue Distinction Centers for Spine Surgery are ...
... ... enhances customer service and Web site features with online customized health plan quotes , ... Chicago, IL (PRWEB) February 22, 2010 ... health insurance, introduces a new Web tool for customized health plan quotes. With a few ...
... , ... ... ... ...
Cached Medicine News:Health News:Mennen Medical Launches the VitaLogik 6000, a Pre-Configured Multi-Parameter Patient Monitor with New High Performance Wireless Technology 2Health News:Mennen Medical Launches the VitaLogik 6000, a Pre-Configured Multi-Parameter Patient Monitor with New High Performance Wireless Technology 3Health News:Home Care Delivered, Inc. Launches a New Vacuum Therapy Category to Service Patients with Erectile Dysfunction 2Health News:Home Care Delivered, Inc. Launches a New Vacuum Therapy Category to Service Patients with Erectile Dysfunction 3Health News:Aprima and Pacific Medical IT Partner to Provide Electronic Health Records to Physician Practices 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 2Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 3Health News:Houston Northwest Medical Center Has Been Designated as a Blue Distinction Center for Spine Surgery 4Health News:Leading Chicago Insurance Company, JMW & Sons, Introduces Online Tool for Customized Health Plan Quotes 2Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 2Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 3Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 4Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 5Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 6Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 7Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 8Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 9Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 10Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 11Health News:Brooke Burke Named Spokeswoman for underWAY(TM), America's First All Natural Appetite Suppressing Beverage & Thirst Quencher 12
BatCup cotyloid implant, designed for use in revision surgery, is an hemispherical metal cup, with grooves on the edges that house locking flanges, which are attached to the iliac bone by cancellous ...
... Metal material and modularity into ... a fusion of technology and versatility ... for initial and long-term stability, but ... shell and liner options to address ...
The cementless biomEx cup can be used with both cemented and cementless femoral stems....
The Trilogy system builds on the success of the Harris/Galante Porous and HGP II cups by combining proven features with new technology designed to inhibit the formation and migration of polyethylene ...
Medicine Products: